Jane Street’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-31,700
| Closed | -$1.51M | – | 11003 |
|
|
2025
Q3 | $1.51M | Sell |
31,700
-15,600
| -33% | -$755K | ﹤0.01% | 5462 |
|
|
2025
Q2 | $2.52M | Sell |
47,300
-325,800
| -87% | -$14.8M | ﹤0.01% | 4047 |
|
|
2025
Q1 | $15.1M | Buy |
373,100
+219,400
| +143% | +$9.3M | ﹤0.01% | 1546 |
|
|
2024
Q4 | $4.28M | Sell |
153,700
-37,600
| -20% | -$1.14M | ﹤0.01% | 2890 |
|
|
2024
Q3 | $5.49M | Buy |
191,300
+21,800
| +13% | +$568K | ﹤0.01% | 2709 |
|
|
2024
Q2 | $3.98M | Sell |
169,500
-2,500
| -1% | -$53.5K | ﹤0.01% | 3332 |
|
|
2024
Q1 | $4.34M | Buy |
172,000
+3,700
| +2% | +$88.9K | ﹤0.01% | 2833 |
|
|
2023
Q4 | $3.93M | Buy |
168,300
+30,300
| +22% | +$598K | ﹤0.01% | 3219 |
|
|
2023
Q3 | $6.98M | Sell |
138,000
-221,500
| -62% | -$10.3M | ﹤0.01% | 2189 |
|
|
2023
Q2 | $16.8M | Buy |
359,500
+283,600
| +374% | +$13M | 0.01% | 1381 |
|
|
2023
Q1 | $2.9M | Sell |
75,900
-129,400
| -63% | -$5.77M | ﹤0.01% | 3199 |
|
|
2022
Q4 | $11.3M | Buy |
205,300
+97,300
| +90% | +$4.17M | 0.01% | 1500 |
|
|
2022
Q3 | $3.68M | Buy |
+108,000
| New | +$1.65M | ﹤0.01% | 3123 |
|
|
2022
Q2 | – | Sell |
-23,000
| Closed | -$326K | – | 9556 |
|
|
2022
Q1 | $326K | Sell |
23,000
-12,400
| -35% | -$217K | ﹤0.01% | 8272 |
|
|
2021
Q4 | $749K | Sell |
35,400
-600
| -2% | -$13.3K | ﹤0.01% | 6496 |
|
|
2021
Q3 | $805K | Buy |
+36,000
| New | +$815K | ﹤0.01% | 6349 |
|
|
2021
Q2 | – | Sell |
-8,500
| Closed | -$247K | – | 9707 |
|
|
2021
Q1 | $247K | Buy |
+8,500
| New | +$257K | ﹤0.01% | 7966 |
|
Other funds holding AKRO
Jane Street's AKRO Position: Q4 2025 in Review
Jane Street sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,949 shares — an estimated $377K sold.
Jane Street first reported a position in AKRO in Q1 2021 and held it in 18 quarters. The position peaked at $12.3M in Q2 2023. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Jane Street reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Jane Street sold 7,949 Akero Therapeutics shares in Q4 2025, an estimated $377K.
- Jane Street first reported a position in Akero Therapeutics in Q1 2021 and held it in 18 quarters.
- Jane Street's Akero Therapeutics position peaked at $12.3M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.